Influenza vaccination has shown itself to be effective in reducing morbidity and mortality in patients with underlying chronic respiratory diseases. Pneumococcal vaccine is effective in reducing the incidence of invasive disease. Therefore, COPD sufferers are a target group to be vaccinated against ...
The effectiveness of pneumococcal vaccine in the immunocompetent elderly remains controversial. We report the results of a multicenter, case-control study ... SIMS,V Richard - 《Annals of Internal Medicine》 被引量: 912发表: 1988年 Randomised trial of 23-valent pneumococcal capsular polysaccharide ...
We assessed the importance of Streptococcus pneumoniae and immunologic response to 14-valent pneumococcal vaccine in a randomized (saline placebo or vaccine) double-blind pilot study involving 103 patients with chronic obstructive pulmonary disease (COPD). Antibody titers, the flora of the sputum, respi...
90471 Immunization administration (includes percutaneous, intradermal, subcutaneous, or intramuscular injections); 1 vaccine (single or combination vaccine/toxoid) +90472 each additional vaccine (single or combination vaccine/toxoid) (List separately in addition to code for primary procedure) HCPCS codes co...
Purpose: In Japan, both a 23-valent pneumococcal polysaccharide vaccine (PPSV23) and a 13-valent pneumococcal conjugate vaccine (PCV13) are available. Although randomized controlled trials have examined the effects of pneumococcal vaccines, few epidemiological studies have investiga...
among the elderly 65 years and older and among persons with underlying medical conditions. However, recent data from the US suggest that the incidence of pneumococcal disease is decreasing as a result of widespread use of protein-conjugate pneumococcal vaccine in children since its licensure in ...
Background Patients with chronic obstructive pulmonary disease (COPD) are at elevated risk of pneumococcal infection. A 13-valent pneumococcal conjugate vaccine (PCV13) was approved for protection against invasive disease and pneumonia c... Jose,Miguel,Rodríguez,... - 《Clinical Drug Investigation》...
The article analyzes results of vaccination against pneumococcal infection of children with recurrent bronchitis using polysaccharide vaccine and its combination with immunomodulator in 64 children aged from 4 to 17 years. Immunopotentiating effect of the immunomodulator was revealed during vaccination against...
Describe how pneumococcal disease manifests in adults. Which manifestations of pneumococcal infection are more often seen in adults than children? What are the potential lethal consequences of pneumococcal infections in adults, such as sepsis or severe pneumonia, and how can vaccination help mitigate th...
Adults 19 or older with chronic health conditions such as COPD, asthma, diabetes, and chronic heart disease face greater risk for pneumococcal pneumonia. 6.1xGreater Risk Adults 65+ are at 6.1x greater risk for pneumococcal pneumonia compared to healthy adults aged 18–64. Over10xMore Likely Adu...